Creates provisions relating to insurance coverage of genetic screenings for cancer risk
Summary
HB1080 creates a new section in Missouri insurance law requiring health benefit plans delivered, issued, renewed, or continued on or after January 1, 2026, to cover genetic counseling and, when indicated after counseling, genetic testing for individuals assessed to be at increased risk of cancer based on a clinical risk assessment tool and a personal or family history of cancer. The bill specifies that the counseling and testing must be provided by appropriately certified individuals recognized by the Department of Commerce and Insurance, and that coverage includes all associated costs for the counseling and any indicated laboratory test.
The bill also prohibits health carriers and health benefit plans from using the results of genetic testing or the fact that genetic counseling was received to determine eligibility, premiums, coverage limits, renewals, or other underwriting decisions. It further bars cost-sharing for the required coverage, subject to a special rule for health savings account-qualified high deductible health plans so the mandate does not conflict with federal HSA rules, except for preventive services that remain covered regardless of deductible status.
Impact
HB1080 would amend Chapter 376, RSMo, by adding section 376.1260 and imposing a new insurance coverage mandate on Missouri health benefit plans and carriers. It would expand required benefits to include cancer-risk genetic counseling and testing, restrict underwriting based on genetic information, and create a statutory violation tied to existing insurance enforcement provisions in section 375.1303. The bill would affect insurers, plan sponsors, enrollees, genetic counselors, and laboratories providing cancer-risk assessment services.
Sentiment
The available record shows no committee transcript, recorded vote, or formal opposition in the provided materials, so there is no documented debate to indicate strong support or resistance. Based on the bill’s structure, it appears aimed at expanding access to preventive genetic services and protecting consumers from adverse insurance treatment based on genetic information, which typically aligns with public-health and patient-protection goals.
Contention
The main potential points of contention are the insurance mandate and the prohibition on cost-sharing, which could raise concerns for insurers and employers about premium impacts and benefit costs. Another likely issue is the interaction with high-deductible health plans and federal HSA rules, since the bill includes a carveout to preserve HSA eligibility. The underwriting restrictions on use of genetic test results may also be a point of concern for carriers because they limit risk-based pricing and coverage decisions.